Citations

Clear

16280 citation(s) found for "Yu, David".

Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults
Daw, Stephen , Cole, Peter D. , Garnier, Nathalie , Buffardi, Salvatore, Mascarin, Maurizio , Lissat, Andrej , Mauz‐Körholz, Christine , Krajewski, Jennifer , Akyol, Alev, Crowe, Russell, Drachtman, Richard A. , Kelly, Kara M. , Leblanc, Thierry , Harker‐Murray, Paul , Hoppe, Bradford S. , Hodgson, David , Beishuizen, Auke , Anderson, Bailey , Xu, Yan , Leblanc, Thierry

Mayo Clinic

JAMA Oncology | January 2, 2025 | Volume: 11 | Issue: 3 | Pages: 249

10.1001/jamaoncol.2024.5627 | PMID 39745739 Get It

ImportanceRetrieval strategies for children, adolescents, and young adults with relapsed classic Hodgkin lymphoma (cHL) aim to maintain efficacy while minimizing long-term toxic effects. Children, adolescents, and young adults with low-risk, relapsed cHL may benefit from replacing high-dose chemotherapy and autologous stem cell transplant with less intensive involved-site radiotherapy (ISRT).ObjectiveTo evaluate a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed cHL with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response and ISRT (30.0 to 30.6 Gy).Design, Setting, and ParticipantsCheckMate 744 (R1 cohort) was a phase 2, nonrandomized, single-arm study enrolling children, adolescents, and young adults aged 5 to 30 years with low-risk cHL between September 25, 2017, and December 16, 2020, across the US, Canada, and Europe. Data were analyzed from September 2017 to November 2022.ExposuresPatients received 4 cycles of nivolumab plus BV induction; patients with complete metabolic response (CMR) received an additional 2 cycles of nivolumab plus BV while patients with suboptimal response received 2 cycles of BV plus bendamustine intensification. Patients with CMR after induction or intensification received ISRT consolidation.Main Outcomes and MeasuresPrespecified coprimary end points were CMR rate (Lugano 2014 classification) any time before ISRT and 3-year event-free survival (EFS) rate, per blinded independent central review (BICR).ResultsOf 28 included patients treated in the low-risk cohort, 18 (64%) were female, and the median (range) age was 17 (6-27) years. At a median (range) follow-up of 31.9 (2.2-55.3) months, CMR per BICR any time before ISRT was 93% (26 of 28; 90% CI, 79.2-98.7; objective response rate [ORR], 100%), and 23 of 28 (82%) achieved CMR per BICR after 4 cycles of nivolumab plus BV (ORR, 96.4%). Kaplan-Meier estimates of EFS and progression-free survival rates at 3 years were 87% (3 of 18; 90% CI, 69.5-94.7) and 95% (1 of 18; 90% CI, 76.7-99.0), respectively. During induction, 22 patients (79%) had treatment-related adverse events, including 7 with grade 3 or 4 adverse events, 2 with anemia, 1 with neutropenia, and 6 with immune-mediated adverse events. Serious adverse events leading to discontinuation occurred in 2 patients.Conclusions and RelevanceThis nonrandomized clinical trial found that for children, adolescents, and young adults with low-risk, relapsed cHL, a transplant-free, risk-adapted, response-based approach with nivolumab plus BV and ISRT offered high CMR rates and high 3-year EFS rate, with a safety profile consistent with that of each agent used.Trial RegistrationClinicalTrials.gov Identifier: NCT02927769
Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma
Milgrom, Sarah A. , Renfro, Lindsay A. , Wu, Yue , Schwartz, Cindy L. , McCarten, Kathleen M. , Kelly, Kara M. , Keller, Frank G. , Hoppe, Bradford S. , Constine, Louis S , Hodgson, David , Castellino, Sharon M.

Mayo Clinic

JAMA Oncology | January 2, 2025 | Volume: 11 | Issue: 3 | Pages: 340

10.1001/jamaoncol.2024.5648 | PMID 39745710 Get It

This nonrandomized clinical trial reports outcomes for children with low-risk relapsed Hodgkin lymphoma treated with second-line chemotherapy and involved-field radiotherapy without autologous stem cell transplant.
Comparative Analysis of Injury and Illness Rates Among Team USA Athletes at the Tokyo 2020 Summer Olympic and Paralympic Games
Post, Eric G. , Cali, Malia G. , Clark, Stephanie C., Noble-Taylor, Kayle E., Robinson, David M. , Hasley, Ike B., Larson, Emily G., McPherson, April L. , Adams, William M. , Adams, William M , Clark, Stephanie C., Robinson, David M., Anderson, Travis , Finnoff, Jonathan T.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | January 2, 2025 | Volume: 13 | Issue: 1 | Pages: No page available

10.1177/23259671241304417 | PMID 39758142 Get It

Background: Previous research has reported higher rates of both injury and illness among Paralympic athletes compared with Olympic athletes during the Winter Olympic and Paralympic Games, but no studies have directly compared injury and illness incidence between Olympic and Paralympic athletes competing in a Summer Games. Purpose: To compare injury and illness rates between Olympic and Paralympic Team USA athletes competing in the Tokyo 2020 Olympic and Paralympic Games. Study Design: Descriptive epidemiology study. Methods: All injuries and illnesses that occurred among the Team USA athletes competing in the Tokyo 2020 Summer Olympic or Paralympic Games were documented. A total of 701 Team USA athletes (53.6% female) competed in the Tokyo 2020 Summer Olympic Games, across 34 different sports. For the Tokyo 2020 Summer Paralympic Games, a total of 245 athletes (51.6% female) competed across 20 sports. Incidence rates (IRs) per 1000 athlete-days were calculated according to sex, sport, anatomic location, and illness type. IR ratios (IRRs) were calculated to compare IRs between male and female athletes and between Olympic and Paralympic athletes. Results: Overall, there were no differences in injury incidence (IRR, 1.18; 95% CI, 0.84-1.68) or illness incidence (IRR, 0.68; 95% CI, 0.41-1.15) between Olympic and Paralympic athletes. Male Paralympic athletes were less likely to sustain an illness compared with female Paralympic athletes (IRR, 0.35; 95% CI, 0.11-0.90). Conclusion: There were no differences in injury or illness rates between Olympic and Paralympic Team USA athletes competing at the Tokyo 2020 Summer Games, contrary to previous comparisons among winter sport athletes. These results challenge the prevailing notion that Summer Paralympic athletes are at greater injury and illness risk, suggesting that factors beyond Olympic or Paralympic Games participation influence health concerns.
Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Hwang, Justin H. , Likasitwatanakul, Pornlada , Deshmukh, Sachin Kumar , Wu, Sharon , Kwon, Jason J. , Toye, Eamon , Moline, David , Evans, Mark G. , Elliott, Andrew , Passow, Rachel , Luo, Christine , John, Emily , McKay, Rana R. , Heath, Elisabeth I. , Nabhan, Chadi , Reizine, Natalie , Orme, Jacob J. , Domingo‐Domenech, Josep , Dehm, Scott M. , Hwang, Justin H , Gandhi, Nishant , McKay, Rana R , Heath, Elisabeth I , Nabhan, Chadi , Reizine, Natalie , Orme, Jacob J , Domingo Domenech, Josep M , Sartor, A Oliver , Baca, Sylvan C , Dehm, Scott M , Antonarakis, Emmanuel S , Elliott, Andrew , Gandhi, Nishant , Sartor, Oliver , Antonarakis, Emmanuel S.

Mayo Clinic

Clinical Cancer Research | January 2, 2025 | Volume: 31 | Issue: 5 | Pages: 936-948

10.1158/1078-0432.ccr-24-3471 | PMID 39745364 Get It

Abstract Purpose: Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain affect protein function. We developed a FOXA1 classification system to inform clinical management. Experimental Design: A total of 5,014 prostate cancer samples were examined using whole-exome and -transcriptome sequencing from the Caris Life Sciences database. We denoted class 1 FOXA1 alterations as missense and in-frame insertions/deletions with subclasses oriented with respect to the FKH domain. These were in the first part of the FKH domain [class 1A: amino acids (AA) 168–246], within the Wing2 region of FKH (class 1B: AA 247–269), or outside FKH (class 1C: AA 1–167, 270+). Two hotspot missense mutations at R219 were denoted class 2. Class 3 included predicted truncating mutations with subclasses partitioned based on the FKH domain (class 3A: AA 1–269 and class 3B: AA 270+). Class 4 represented FOXA1 amplifications. Real-world overall survival and therapy outcomes were determined from insurance claims. Results: FOXA1 alterations did not influence survival when considered in aggregate but had distinct prognostic effects when stratified by class. In primary prostate samples, class 1A alterations were associated with overall improved survival (HR, 0.57; P = 0.03); a similar trend was seen in metastatic biopsies with class 1B (HR, 0.84; P = 0.09). Conversely, in primary specimens, class 1C exhibited worse survival upon second-generation androgen receptor signaling inhibitor treatment (HR, 1.93; P < 0.001). Class 2 mutations (R219C/S) were enriched in neuroendocrine prostate cancers and were associated with overall poor survival (HR, 2.05; P < 0.001) and worse outcomes to first-line androgen-deprivation therapies (HR, 2.5; P < 0.001). Class 3A alterations indicated improved survival (HR, 0.70; P = 0.01), whereas class 3B alterations portended poor outcomes (HR, 1.50; P < 0.001). Amplifications (class 4) indicated poor outcomes in metastatic samples (HR, 1.48; P = 0.02). Molecularly, different FOXA1 alteration classes harbored distinct mutational and immunologic features as well as unique transcriptional programs. Finally, relative to European Americans, African Americans had increased class 1C alterations, whereas Asian/Pacific Islander patients had increased class 1B alterations. Conclusions: FOXA1 alterations should not be interpreted in aggregate, as different classes are associated with divergent molecular features and clinical outcomes. Our revised classification schema facilitates clinical decision-making for patients with prostate cancer and uncovers important racial differences.
Contemporary nonsurgical management of Peyronie's disease
Pinkhasov, Alexandr, Tentis, Elise, Ziegelmann, Matthew , Pinkhasov, Alexandr M, Yang, David Y.

Mayo Clinic

Current Opinion in Urology | January 2, 2025 | Volume: 35 | Issue: 2 | Pages: 135-141

10.1097/mou.0000000000001255 | PMID 39744754 Get It

Purpose of review Peyronie's disease characterizes a condition in which there is angular curvature of the penis. We know that the most patients with Peyronie's disease will not have spontaneous resolution of their penile curvature. As such, patients who desire treatment can elect for either surgical or nonsurgical therapy. Herein, we discuss the contemporary nonsurgical management options for Peyronie's disease. Recent findings Nonsurgical management options for Peyronie's disease include oral therapy, intra-lesional injections, and penile traction therapy. At the time of this review, there is essentially no high-level evidence demonstrating any benefit for oral therapy. Penile traction therapy has evolved over the past decade with second-generation devices demonstrating strong efficacy and more convenient treatment regimens. Intra-lesional options include collagenase Clostridium histolyticum (CCH), verapamil, and interferon alpha-2b. The IMPRESS trial garnered the strongest level of evidence (two randomized, double-blind, placebo-controlled trials) to support the safety and efficacy of CCH. Verapamil is an option supported by several urological societies; however, the evidence supporting its efficacy is inconsistent between several notable series and randomized studies. IFN alpha 2b can produce modest improvement in curvature, however, is not available for use in North America. Summary Herein, we will discuss notable advances in nonsurgical management of Peyronie's disease.
CORR Insights®: Is It Possible to Develop a Patient-reported Experience Measure With Lower Ceiling Effect?
Ring, David , Crijns, Tom Joris

Mayo Clinic

Clinical Orthopaedics & Related Research | January 2, 2025 | Volume: 483 | Issue: 4 | Pages: 704-706

10.1097/corr.0000000000003343 | PMID 39745237 Get It

EVALUATING IN-HOME ASSISTIVE TECHNOLOGY FOR DEMENTIA CAREGIVERS: CHALLENGES AND OPPORTUNITIES
Chen, Kuan‐Hua , Scheffer, Julian A. , Merrilees, Jennifer , Hinderberger, Brian, Wang, Gene, Levenson, Robert W. , Levenson, Robert W , Yee, Claire , Moss, David

Mayo Clinic

Innovation in Aging | January 1, 2025 | Volume: 8 | Issue: Supplement_1 | Pages: 435-435

10.1093/geroni/igae098.1415 Get It

Abstract Dementia caregivers are at heightened risk for developing mental and physical health problems. Interventions designed to protect caregiver health often create additional demands on time and energy (e.g., exercise programs). Technology-based interventions (e.g., remote monitoring) can be effective, scalable, and do not add greatly to caregiver burden. Through a collaboration with a local technology company, Care Daily, we conducted two randomized controlled trials to evaluate People Power Caregiver (PPCg), a system of sensors in the home connected to cloud-based AI that alerts caregivers about worrisome deviations from normal patterns (e.g., care-recipient’s falls, wandering). Across two studies (study 1: 9-month duration with professional installation of PPCg; study 2: 6-month duration with caregiver self-installing the PPCg using remote tech support), 284 caregivers were recruited; 261 completed initial study deployment (e.g., system installation); and 235 completed the entire study protocol. Use of PPCg was associated with (a) reduced caregiver anxiety in study 1; (b) greater protection from declines in sleep efficiency in studies 1 and 2. These findings underscore the promise of technology-based intervention to mitigate health problems in dementia caregivers. However, challenges and complexities in recruitment (e.g., remote consenting both caregivers and care recipients), retention (e.g., due to changes in home environment or caregiving status), system installation (e.g., working with caregivers with less experience using technology), data quality assurance (e.g., invalid sensor data) as well as our efforts to overcome these challenges have been instructive. Lessons learned from these studies can provide useful guidance for future large-scale, technology-based interventions for dementia caregivers.
Common Questions and Misconceptions About Energy Drinks: What Does the Scientific Evidence Really Show?
António, José , Antonio, Brandi , Arent, Shawn M. , Candow, Darren G. , Escalante, Guillermo , Evans, Cassandra , Forbes, Scott C. , Fukuda, David H. , Gibbons, Maureen, Jagim, Andrew R. , Kerksick, Chad M. , Kurtz, Jennifer A. , Lillis, Joseph , Lowery, Lonnie , Mastrofini, Gianna F. , Mills, Scotty, Nelson, Michael T. , Pereira, Flavia , Roberts, Justin , Sagner, Michael , Stout, Jeffrey R. , Wells, Adam J. , Forbes, Scott C , Fukuda, David , Jagim, Andrew R , Kerksick, Chad M , Kurtz, Jennifer A , Lowery, Lonnie , Mastrofini, Gianna F , Pereira, Flavia , Roberts, Justin , Stout, Jeffrey R , Wells, Adam , Antonio, Jose , Arent, Shawn M , Harty, Patrick S. , Kalman, Douglas , Tartar, Jaime L.

Mayo Clinic

Nutrients | January 1, 2025 | Volume: 17 | Issue: 1 | Pages: 67

10.3390/nu17010067 | PMID 39796501 Get It

Energy drinks are a commonly consumed beverage, and studies suggest a possible performance-enhancing effect. A Google Scholar search using the keywords “energy drinks” and “exercise” yields numerous results, underscoring the voluminous research on this topic. However, there are questions regarding the effectiveness and safety of energy drinks. These questions include, but are not limited to: (1) What are the main active ingredients in energy drinks? (2) Do energy drinks assist in weight management? (3) Do energy drinks enhance aerobic performance? (4) Do energy drinks enhance athletic speed? (5) Do energy drinks improve reaction time? (6) Do energy drinks enhance lean tissue mass? (7) Can energy drinks improve cognitive performance? (8) Does the acute consumption of energy drinks elevate resting energy expenditure? (9) Is there any evidence to suggest that energy drinks are more effective than an identical serving of caffeine alone? (10) Are there sex differences in the response to energy drink consumption? (11) Do energy drinks affect sleep or sleepiness? (12) Should pregnant women avoid energy drinks? (13) Do energy drinks adversely affect cardiovascular function? (14) Does consuming energy drinks cause brain damage? (15) What are other safety considerations regarding energy drinks? (16) Is there any evidence to suggest that energy drinks are more effective than an identical serving of caffeine alone? (17) If caffeine is the main active ingredient in energy drinks and coffee, why is there a discrepancy in the adverse events reported for each? To address these questions, we performed an evidence-based scientific evaluation of the literature on energy drink supplementation.
Novel inhibitory effect of Omega-3 fatty acids regulating pancreatic cancer progression
Garay, M.I., Mazo, Tamara , Ferrero, Victoria, Barotto, N.N. , Lagares, Clarisa, Granton, María F, Moreira‐Espinoza, María José , Cremonezzi, David , Tolosa, Ezequiel J. , Fernández-Zapico, Martín E. , Pasqualini, María Eugenia , Fernandez-Zapico, Martin E , Pasqualini, María E , Ferrero, Victoria, Comba, Andrea , Brunotto, Mabel Noemí

Mayo Clinic

Carcinogenesis | January 1, 2025 | Volume: 46 | Issue: 1 | Pages: No page available

10.1093/carcin/bgae081 | PMID 39742417 Get It

Abstract Pancreatic cancer is a devastating malignancy in great need of new and more effective treatment approaches. In recent years, studies have indicated that nutritional interventions, particularly nutraceuticals, may provide novel avenues to modulate cancer progression. Here, our study characterizes the impact of ω-3 polyunsaturated fatty acids, eicosapentaenoic acid, and docosahexaenoic acid, as a nutraceutical intervention in pancreatic cancer using a genetically engineered mouse model driven by KrasG12D and Trp53R172H. This model closely resembles human pancreatic carcinogenesis, offering a disease relevant platform for translational research. Our findings showed that ω-3 polyunsaturated fatty acids intervention (using a diet supplemented with 6% cod liver oil) significantly reduced tumor volume as well as lung and liver metastasis and a trend toward improved survival rate compared with control treated mice. This antitumoral effect was accompanied by distinct changes in tumor membrane fatty acid profile and eicosanoids release. Furthermore, the eicosapentaenoic acid and docosahexaenoic acid intervention also reduced malignant histological parameters and induced apoptosis without affecting cell proliferation. Of note is the significant reduction in tumor fibrosis that was associated with decreased levels of Sonic Hedgehog, a major ligand controlling this cellular compartment in pancreatic cancer. All together our results demonstrate the impact of eicosapentaenoic acid and docosahexaenoic acid as antitumor regulators in pancreatic cancer, suggesting potential for ω-3 polyunsaturated fatty acids as a possible antitumoral dietary intervention. This research opens new avenues for integrating nutraceutical strategies in pancreatic cancer management.
Evaluating the factor structure of the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV) in adults with congenital heart disease
Dawkins-Henry, Onella S. , Bernstein, Jane Holmes, Bellinger, David C., Gurvitz, Michelle , Cassidy, Adam R. , Semmel, Eric S, Semmel, Eric S. , Wypij, David , Calderon, Johanna , Newburger, Jane W.

Mayo Clinic

The Clinical Neuropsychologist | December 31, 2024 | Volume: 39 | Issue: 7 | Pages: 2021-2032

10.1080/13854046.2024.2442424 | PMID 39741381 Get It